• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Semaphorin 3F inhibits breast tumor angiogenesis and metastasis via Akt-mTOR pathway.

Research Project

Project/Area Number 17K10553
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field General surgery
Research InstitutionEhime University

Principal Investigator

Kamei Yoshiaki  愛媛大学, 医学部附属病院, 講師 (90623702)

Co-Investigator(Kenkyū-buntansha) 中山 寛尚  広島国際大学, 保健医療学部, 講師 (40512132)
Project Period (FY) 2017-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords軸索誘導因子 / セマフォリン / 転移 / 乳癌 / 血管新生 / セマフォリン3F / mTOR
Outline of Final Research Achievements

Semaphorin 3F (SEMA3F), a member of class three semaphorin, is a potent inhibitor of angiogenesis and tumor progression in various tumors. In this study, we evaluated the function of SEMA3F using breast tumor cells in vitro and in vivo. As a result, SEMA3F inhibited phosphorylation of Akt and mTOR signaling in breast cancer cells. We also examined the effect of SEMA3F on breast tumor progression in vivo allograft model. We found that tumor volume was significantly inhibited in SEMA3Finjected mice compared to controls. Importantly, we observed that mice treated with SEMA3F had minimal metastasis into the liver and lung, compared to controls. We conclude that SEMA3F is a promising inhibitor of breast tumor growth, angiogenesis and metastasis.

Academic Significance and Societal Importance of the Research Achievements

乳癌の罹患率は女性の癌の中で最も高く、現在でも増加の一途をたどっている。一方で、分子標的薬ハーセプチンの登場によって1年生存率が大きく改善したが、ハーセプチンへの元々の耐性や獲得耐性も大きな課題となっており、乳癌を克服するためには新たな治療薬の開発が必要である。本研究で着目したセマフォリン3Fは乳癌細胞の浸潤能を抑制し、動物実験においても肝臓・肺への転移を抑制することが明らかとなった。この効果を利用し、既存の抗癌剤と併用することによって、より効果的な治療が望めると考えており今後の研究で追及していく。

Report

(4 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (3 results)

All 2018 2017

All Presentation (3 results) (of which Int'l Joint Research: 1 results)

  • [Presentation] Semaphorin 3F inhibits breast tumor angiogenesis and metastasis via Akt-mTOR pathway.2018

    • Author(s)
      Hironao Nakayama, Ayumi Nakazawa, Natsuki Sawatari, Akari Murakami, Hisayo Nishida-Fukuda, Yoshiaki Kamei, Yasutsugu Takada and Shigeki Higashiyama
    • Organizer
      International Vascular Biology Meeting 2018
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] セマフォリン3Fは乳癌の血管新生と転移を抑制する.2017

    • Author(s)
      中山寛尚, 村上朱里, 福田尚代, 亀井義明, 高田泰次, 東山繁樹.
    • Organizer
      生命科学系学会合同年次大会 第90回日本生化学会
    • Related Report
      2017 Research-status Report
  • [Presentation] Semaphorin 3F inhibits breast tumor angiogenesis and metastasis via Akt-mTOR pathway.2017

    • Author(s)
      Hironao Nakayama, Akari Murakami, Hisayo Nishida-Fukuda, Yoshiaki Kamei, Yasutsugu Takada and Shigeki Higashiyama.
    • Organizer
      第76回日本癌学会学術総会
    • Related Report
      2017 Research-status Report

URL: 

Published: 2017-04-28   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi